Stifel Financial
IOBT

Stifel Financial’s IO Biotech IOBT Stock Holding History

Stifel Financial’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$53K – 3396
2022
Q1 		$53K Hold
10,000
– – ﹤0.01% 3305
2021
Q4 		$64K Buy
+10,000
New +$96.6K ﹤0.01% 3292

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stifel Financial's IOBT Position: Q2 2022 in Review

Stifel Financial sold out of IO Biotech (IOBT) in Q2 2022, closing a stake of 10,000 shares — an estimated $53K sold.

Stifel Financial first reported a position in IOBT in Q4 2021 and held it in 2 quarters. The position peaked at $64K in Q4 2021. 18 funds tracked by Wall St. Rank hold IOBT as of Q2 2022.

  • Stifel Financial reported no remaining IO Biotech position as of Q2 2022 after selling out during the quarter.
  • Stifel Financial sold 10,000 IO Biotech shares in Q2 2022, an estimated $53K.
  • Stifel Financial first reported a position in IO Biotech in Q4 2021 and held it in 2 quarters.
  • Stifel Financial's IO Biotech position peaked at $64K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held IO Biotech as of Q2 2022.

Based on Stifel Financial's 13F filing for Q2 2022, filed 15 Aug 2022.